Biomarker for tumor detection
By constructing miRNAs combination models of mir-21-3p, mir-10b-5p, mir-133a-3p, mir-195-5p and mir-155-3p, the limitations of early breast cancer screening were solved and the Early, non-invasive and accurate diagnosis of breast cancer provides an efficient biomarker panel.
Patent Information
- Application Number
- CN202411340935.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-25
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-09-25
AI Technical Summary
The existing early screening methods for breast cancer have limitations, making it difficult to detect and distinguish between breast cancer and benign diseases early, and lack effective non-invasive biomarkers.
A specific set of miRNAs combinatorial models were constructed, including mir-21-3p, mir-10b-5p, mir-133a-3p, mir-195-5p and mir-155-3p, and serum samples were detected by RT-qPCR and evaluated Its diagnostic ability and specificity in breast cancer diagnosis.
A diagnostic combination model with high sensitivity and strong specificity was established. The AUC was shown to be 0.948 through ROC curve analysis, providing an early-stage, non-invasive and accurate diagnostic tool for breast cancer.
Smart Images

Figure CN118932069A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of disease detection, and in particular to a biomarker for tumor detection. Background Art
[0002] Breast Cancer (BC) is a highly prevalent malignant tumor that seriously endangers women's health and life. According to statistics from the International Agency for Research on Cancer (IARC) in 2022, the global incidence of breast cancer is second only to lung cancer, with nearly 2.3 million new cases and more than 660,000 new deaths. The choice of treatment options and prognosis for BC patients are closely related to early detection. In recent years, the survival rate of BC patients has significantly improved with the continuous development of screening and treatment methods, but the 5-year overall survival rate of advanced patients is only 20%. Early diagnosis of BC disease and further guidance of treatment and improvement of prognosis are the key tasks in BC research at this stage. Commonly used auxiliary examination methods in clinical practice include breast ultrasound, molybdenum target and tissue biopsy, among which tissue biopsy is currently the preferred method for obtaining tumor molecular information. In view of the limitations of the current early screening methods, new examination methods need to be developed and applied to clinical practice.
[0003] MicroRNA (miRNA) is a single-stranded non-coding RNA sequence consisting of 20-22 nucleotides in length. It is widely present in humans, animals, plants, etc. and is involved in RNA-mediated gene silencing. As people's understanding of miRNA increases, studies have found that abnormal expression of miRNA genes can cause functional disorders and lead to diseases, especially cancer-related diseases. It has a high reference value in distinguishing normal tissues and tumor subtypes. At the same time, due to its relatively simple molecular structure, its extremely high tissue specificity and stability, and its easy quantification and amplification make miRNAs a promising potential biomarker.
[0004] There is a lot of evidence that miRNA plays a vital role in the carcinogenesis of various cancers, such as clear cell renal cell carcinoma, oral squamous cell carcinoma, and prostate cancer. Studies have shown that miRNA plays an important role in the biological functions of cancer cells, such as proliferation, differentiation, apoptosis, and invasion, and has become one of the key factors in regulating the occurrence and development of cancer. The issue of specific miRNA as a marker for tumor diagnosis and prognosis has gradually attracted the attention of more and more scholars, providing new ideas for the development of cancer diagnosis and treatment.
[0005] Breast cancer (BC) is one of the most common types of malignant tumors, and its incidence and mortality are increasing year by year. Breast cancer usually does not show obvious symptoms in the early stages and is difficult to distinguish from benign breast diseases. This study aims to use serum to identify a group of specific miRNAs as a non-invasive biomarker for early detection of BC. Summary of the invention
[0006] The object of the present invention is to provide a biomarker for tumor detection.
[0007] Existing research results have confirmed that miRNA expression may be associated with the occurrence and prognosis of breast cancer, but there is still a lack of understanding of the impact of many miRNAs on its development. This study aims to construct a set of specific miRNAs combination models to explore their value in diagnosing BC and help identify BC patients in a timely manner.
[0008] The present invention solves the technical problem by adopting the following technical solutions:
[0009] In a first aspect, the present invention provides a biomarker for tumor detection, wherein the biomarker comprises at least one of mir-21-3p, mir-10b-5p, mir-133a-3p, mir-195-5p, and mir-155-3p.
[0010] In some embodiments of the invention, the biomarkers include:
[0011] miR-155-3p; and
[0012] At least one of mir-21-3p, mir-10b-5p, mir-133a-3p, and mir-195-5p.
[0013] In some embodiments of the invention, the biomarkers include miR-10b-5p, miR-133a-3p and miR-195-5p.
[0014] In some embodiments of the invention, the biomarkers include miR-10b-5p, miR-133a-3p, miR-155-3p and miR-195-5p.
[0015] In some embodiments of the present invention, the biomarkers include mir-21-3p, mir-10b-5p, mir-133a-3p, mir-195-5p and mir-155-3p.
[0016] The reagents for detecting miRNA by RT-qPCR for 5 miRNAs were purchased routinely, and the source was: reverse transcription kit (R323-01, Novozymes, China).
[0017] The nucleotide sequences of the five miRNAs are shown in Table 1:
[0018] miRNA Nucleotide sequence source miR-21-3p CAACACCAGUCGAUGGGCUGU miRBase database miR-10b-5p UACCCUGUAGAACCGAAUUUGUG miRBase database miR-133a-3p UUUGGUCCCCUUCAACCAGCUG miRBase database miR-195-5p UAGCAGCACAGAAAUAUUGGC miRBase database miR-155-3p CUCCUACAUAUUAGCAUUAACA miRBase database
[0019] Table 1
[0020] In some embodiments of the present invention, the biomarkers include mir-21-3p, mir-10b-5p, mir-133a-3p, mir-195-5p and mir-155-3p in the blood.
[0021] In some embodiments of the present invention, the tumor is breast cancer, gastric cancer, lung cancer, esophageal cancer, colorectal cancer, pancreatic cancer, or liver cancer.
[0022] In some embodiments of the present invention, the tumor is breast cancer.
[0023] The present invention includes the following beneficial effects: This study mainly includes a screening stage, a testing stage and a validation stage. In the screening stage, 8 miRNAs related to BC were selected for analysis through literature reading. In the testing stage, 5 miRNAs with the most significant expression differences in 15 BC patients and 15 breast benign controls were selected by quantitative reverse transcription polymerase chain reaction (qRT-PCR) to enter the next stage. In the subsequent validation stage, these 5 miRNAs obtained from serum samples of another 75 BC patients and 50 benign control patients were evaluated using RT-qPCR. The receiver operating characteristic (ROC) curve and area under the curve (AUC) were used to evaluate the diagnostic ability, specificity and sensitivity of the candidate miRNAs. Finally, the above 5 miRNAs were used to construct an optimal diagnostic combination model with high sensitivity and strong specificity.
[0024] The expression levels of mir-21-3p, mir-10b-5p, mir-133a-3p, mir-195-5p and mir-155-3p in the serum of BC patients were significantly lower than those in benign controls, and the expression level of mir-195-3p was higher than that in benign controls. To evaluate its diagnostic potential for BC, we used receiver operating characteristic (ROC) curve analysis. The analysis showed that all five miRNAs showed strong diagnostic ability for BC, with the area under the curve (AUC) > 0.8. To further improve the diagnostic accuracy, we constructed a final diagnostic combination model consisting of these five miRNAs, which showed good diagnostic value with an AUC of 0.948.
[0025] The serum biomarker panel consisting of five miRNAs identified in this study (mir-10b-5p, mir-133a-3p, mir-195-5p, mir-195-3p, and mir-155-3p) offers promise for early, noninvasive, and accurate diagnosis of BC. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 This is the differential expression diagram of the 8 candidate miRNAs in 2.2.
[0027] Figure 2 Figure 2.3 shows the differential expression and ROC curve of the five candidate miRNAs.
[0028] Figure 3 for Figure 3 This is the ROC curve for the evaluation of model No. 25 after combining 5 miRNAs.
[0029] Figure 4 miRWalk3.0 predicted the target genes of 5 miRNAs and performed GO functional annotation and KEGG pathway enrichment analysis.
[0030] Unless stated to the contrary, the terms used in the specification and claims have the following meanings.
[0031] As used herein, the term "prevention" refers to preventing the occurrence of a disease and / or preventing the recurrence of a disease. DETAILED DESCRIPTION
[0032] Combined detection of 5 miRNAs in breast cancer
[0033] 1 Experimental methods
[0034] 1.1 Participants
[0035] The participants of this study included 90 BC patients and 65 benign control volunteers. The recruited patients were all patients who visited the Department of Breast Surgery, the First Affiliated Hospital of Xinjiang Medical University from March 2023 to March 2024. All BC patients were diagnosed by preoperative puncture or postoperative histopathology. None of the patients included in this study received any clinical treatment before collecting serum specimens.
[0036] All patients enrolled had primary BC without metastasis or other cancers. All benign control volunteers had no history of any acute or chronic diseases or other tumors.
[0037] 1.2 Collection and processing of blood samples
[0038] The following collection and sampling procedures were used to obtain serum samples from patients and controls: After enrollment, all participants collected 5-10 mL of circulating blood in the morning on an empty stomach, placed in a sterile anticoagulant tube, and centrifuged at 3000r for 10 min at room temperature. The supernatant was transferred to a microcentrifuge tube and stored in a -80°C refrigerator for subsequent experiments.
[0039] 1.3 Study design
[0040] The study was conducted in four phases.
[0041] First, through extensive literature reading, 8 differential miRNAs that were significantly associated with BC expression were found and screened as candidate biomarkers.
[0042] Secondly, these candidate biomarkers were further tested and validated. In the testing phase, quantitative reverse transcription polymerase chain reaction (RT-qPCR) was performed using 15 BC patients and 15 benign controls to evaluate the relative serum levels of candidate miRNAs, and the top five miRNAs that showed the most significant differences in this phase were selected for further study.
[0043] Then, this study expanded the sample size and repeated the above steps using serum samples from 75 BC patients and 50 benign control patients to validate the results of the previous stage. The expression levels and diagnostic abilities of candidate miRNAs were determined, and the diagnostic combination model was composed of candidate miRNAs to improve the sensitivity and specificity of diagnosis.
[0044] Finally, the potential biological functions of candidate miRNAs related to BC occurrence were explored through bioinformatics analysis.
[0045] 1.4 RNA extraction and detection
[0046] cDNA synthesis was performed on a thermocycle instrument (T100, Bio-Rad, USA) using a reverse transcription kit (R323-01, Novozyme, China) with reverse transcription conditions of 42°C for 5 minutes, 37°C for 15 minutes, and 85°C for 5 seconds. Then, qPCR was performed on an ABIQuantStudio 5 instrument with the program set to 95°C pre-denaturation for 10 minutes, 95°C denaturation for 15 seconds, 60°C annealing and extension for 1 minute, and 40 cycles of denaturation and extension. Three technical replicates were performed for each sample.
[0047] Next, the relative expression of each transcript mRNA was calculated, and GAPDH was used as the internal reference gene for standardization. -ΔΔCTMethods Analyses were performed as described (Livak and Schmittgen 2001). Statistical analyses were performed using GraphPad Prism software (version 8.0, San Diego, CA) with two-way ANOVA or Student's Student ...
[0048] 1.5 Bioinformatics analysis
[0049] miRWalk (http: / / mirwalk.umm.uni-heidelberg.de / ) was used to analyze the target genes of the five miRNAs in the three databases of miRDB, mirTarBase and TargetScan, and a Venn diagram was drawn to visualize the results. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to analyze the main biological functions of the five target miRNAs, as well as the predicted pathways and related functions.
[0050] 1.6 Statistical analysis
[0051] Data from this study were analyzed using SPSS software. The Shapiro-Wilk normality test was used to test whether continuous variables conformed to normal distribution. Categorical variables in different groups were expressed as percentages, while continuous variables (conforming to normal distribution) were expressed as mean ± standard deviation. Statistical significance was defined as p value less than 0.05. To compare the levels of miRNAs between BC and benign control samples, t-test was used for continuous variables and χ2 test was used for categorical variables. The receiver operating characteristic (ROC) curve and area under the ROC curve (AUC) were used to evaluate the diagnostic performance of each candidate miRNA. These measures were used to evaluate the specificity, sensitivity, and overall diagnostic ability of each miRNA. In addition, we calculated the Youden index (J = sensitivity + specificity - 1) to determine the combination of miRNAs that provided the highest sensitivity and specificity for diagnosis.
[0052] 2 Experimental results
[0053] 2.1 Clinical and demographic characteristics of study participants
[0054] A total of 155 participants were included in this study, including 90 BC patients and 65 volunteers with benign breast lesions. Table 1 shows the demographic and clinical characteristics of the participants in the testing and validation phases. The results showed that the average age of the BC group was 49.9±7.5, and the average age of the benign control group was 44.5±9.8. There were no significant differences in age and menopausal status among the participants. The average age of the participants included in the study after the sample expansion was 51.5±7.0, and the average age of the benign control group was 40.4±9.5. They had significant differences in age and menopausal status, which may be due to hormonal effects. Reproductive factors such as age and menopausal status are particularly closely related to the occurrence of BC.
[0055] Table 1 General demographic characteristics of the included study participants
[0056]
[0057]
[0058] 2.2 Confirmation of candidate miRNAs
[0059] Through a large number of literature reviews, we selected and refined the candidate miRNAs related to BC, and selected the miRNAs related to BC as the candidate miRNAs for subsequent research in this study (Table 2). The miRNA precursor will produce two complementary functional mature miRNAs, which are generally processed from the 5' end arm and 3' end arm of the precursor, named "-5p" and "-3p" respectively, and they target different sites respectively. Therefore, a total of 8 complementary miRNAs were included in this study.
[0060] Table 2 Diagnostic value of different miRNAs in breast cancer patients
[0061]
[0062]
[0063] To evaluate the serum levels of eight selected candidate miRNAs, we performed RT-qPCR in a random subpopulation of 15 BC patients and 15 benign controls. Figure 1 The differential expression diagram of 8 candidate miRNAs. Our study found that mir-10b-5p ( Figure 1 B) mir-133a-3p( Figure 1 C) and mir-155-3p( Figure 1 E), mir-195-3p( Figure 1 G) and mir-195-5p( Figure 1 H) had significant differences in expression levels.
[0064] Based on these findings, further analysis focused on these five miRNAs. After univariate analysis, we found that all five miRNAs included in the analysis were significantly associated with the occurrence of breast cancer (Table 3).
[0065] Table 3 Univariate analysis of 5 miRNAs and BC occurrence
[0066]
[0067] 2.3 Diagnostic value of the five candidate miRNAs
[0068] To further validate the potential of the five selected miRNAs as serum biomarkers for BC screening, we expanded the sample size. 75 BC patients and 50 benign controls were included in the study. RT-qPCR was used to detect the relative serum levels of the five miRNAs.
[0069] In our study, Figure 2 Figure 2.3 shows the differential expression and ROC curve of the five candidate miRNAs. Figure 2 A), mir-133a-3p( Figure 2 B) mir-155-3p( Figure 2 C) and mir-195-5p( Figure 2 E) were significantly lower than those in the benign control, and mir-195-3p ( Figure 2 D) The expression level in BC is higher than that in benign controls.
[0070] To evaluate the diagnostic value of these five miRNAs, we performed ROC curve analysis. The area under the ROC curve (AUC) of each miRNA is shown in Figure 2 FJ. Then the Youden index was used to calculate the optimal cut-off value, specificity and sensitivity for diagnosing BC using the five miRNAs (Table 4). As can be seen from the ROC curve, mir-10b-5p, mir-133a-3p, mir-195-5p, mir-195-3p and mir-155-3p showed good diagnostic potential for BC, with AUCs of 0.85, 0.84, 0.87, 0.62 and 0.83, respectively.
[0071] Table 4 Optimal cut-off values, specificity and sensitivity of 5 miRNAs for diagnosing BC
[0072] Target miRNA Cutoff value AUC Sensitivity Specificity Accuracy miR-10b-5p 0.50 0.85 0.69 0.96 0.80 miR-133a-3p 0.41 0.84 0.64 1.00 0.78 miR-155-3p 0.54 0.83 0.70 0.90 0.78 miR-195-3p 0.74 0.62 0.47 0.92 0.65 miR-195-5p 0.96 0.87 0.65 1.00 0.79
[0073] 2.4 Construction of the optimal diagnostic model
[0074] In the experimental stage, we found that mir-10b-5p, mir-133a-3p, mir-195-5p, mir-195-3p and mir-155-3p had good diagnostic ability for BC. Therefore, we investigated whether the combination of several miRNAs had a higher diagnostic value for BC and determined the best combination for BC diagnosis from all possible combinations of miRNAs (Table 5).
[0075] Specificity and sensitivity of all combined models of miRNA in Table 55
[0076]
[0077]
[0078] The study found that except for the three diagnostic models 15, 17 and 21, almost all the constructed models had extremely high specificity (>0.90), which suggests that all our models can accurately identify the occurrence of breast cancer. In addition, the study found that models 4, 19 and 24 all had high diagnostic value (AUC>0.90), which may be because they jointly incorporated miR-10b-5p and miR-195-5p, which are the best diagnostic single miRNAs.
[0079] Model 25 consisted of 5 miRNAs, and this model had a very high diagnostic ability, with the ROC curve showing an AUC of 0.948 (95% CI: 0.914–0.981; specificity = 100%, sensitivity = 79%). The formula of the model was: Logit (P) = 0.757 + (-46.427*miR-10b-5p) + (29.354*miR-133a-3p) + (-20.170*miR155-3p) + (3.144*miR-195-3p) + (17.138*miR-195-5p). Figure 3 This is the ROC curve of the evaluation of model No. 25 after combining 5 miRNAs. This result is better than each single miRNA. Figure 3 shown.
[0080] 2.5 Bioinformatics analysis of five miRNAs
[0081] miRNAWalk2.0 was used to explore and visualize the potential target genes of mir-10b-5p, mir-133a-3p, mir-155-3p, mir-195-5p, and mir-195-3p ( Figure 4 In addition, the potential target genes of the above 5 miRNAs were included in the KEGG pathway enrichment analysis and GO function to further analyze their potential functions. Figure 4miRWalk3.0 predicted the target genes of 5 miRNAs and performed GO functional annotation and KEGG pathway enrichment analysis.
[0082] These findings suggest that the target genes of mir-10b-5p, mir-133a-3p, mir-195-5p, mir-195-3p, and mir-155-3p are involved in key pathways and processes related to cancer development and progression. GO analysis results showed that the above miRNAs are mainly involved in biological processes such as WNT-mediated cell-cell signaling, WNT signaling pathway, and mitotic cell cycle phase transition ( Figure 4 F), and is also involved in cell junctions, transcriptional regulatory complexes, and transferase complexes, transferring phosphorus-containing groups and other cell components ( Figure 4 G). In addition, our study also found that they are also involved in molecular functions such as DNA binding transcription factor binding and protein serine / threonine kinase activity ( Figure 4 H). KEGG analysis results showed that the above five miRNAs mainly play a role by mediating microRNAs in cancer, PI3K-Akt signaling pathway and cell senescence ( Figure 4 I). The enrichment of these target genes in the above pathways reflects their potential roles in regulating key cellular functions associated with tumorigenesis.
[0083] Summarize
[0084] BC is one of the most common types of malignant tumors. In recent years, the incidence and mortality of BC have increased year by year, and the age of onset has shown a trend of younger age. BC usually does not show obvious symptoms in the early stages, is not easy to detect during routine physical examinations, and is difficult to distinguish from benign breast diseases. However, as the disease progresses, the tumor may become malignant and metastatic, resulting in a poor prognosis. Therefore, early diagnosis of BC is challenging. The emergence of biomarkers is helpful for the clinical diagnosis of BC. At present, some serum markers have been found to have a certain relationship with the onset of BC and have been clinically verified. In recent years, some non-coding RNAs have also been studied to help diagnose BC. miRNA is a short non-coding ribonucleic acid (ncRNA) present in biological fluids. Because of its extremely high tissue specificity and stability, it has been increasingly used to distinguish normal tissues and tumor subtypes. Previous studies have shown that plasma miRNAs can be used as biomarkers for detecting BC.
[0085] This study first selected 8 miRNAs with diagnostic potential in BC through extensive literature reading and sorting. The diagnostic value of these 8 miRNAs in BC was detected by analyzing the sera of 15 benign controls and 15 BC patients. The results confirmed that the expression levels of mir-10b-5p, mir-133a-3p, mir-195-5p and mir-155-3p were significantly lower than those in healthy controls, and the expression level of mir-195-3p in BC was higher than that in healthy controls. These expression differences suggest that these miRNAs may be involved in the development and progression of BC.
[0086] In terms of diagnostic potential, ROC curve analysis showed that the above five miRNAs all showed significant diagnostic ability, indicating that these miRNAs have the potential to be used as non-invasive biomarkers for early detection and diagnosis of BC. We then expanded the sample size to 75 breast cancer patients and 50 benign control patients for further verification. Based on the above five high-quality miRNAs, we successfully established an optimal diagnostic panel with high sensitivity and strong specificity. Previous studies have explored the diagnostic efficacy of the above five miRNAs alone, but no studies have yet included the above five miRNAs in diagnostic tools. Our study found that the diagnosis and efficacy of the combined panel are better than each single miRNA. Therefore, the above five miRNAs combined into a diagnostic combination panel can be considered as a new biomarker for diagnosing breast cancer.
[0087] MiR-195-3p and mir-195-5p belong to the miR-195 family and are involved in the occurrence and development of a variety of tumors. Studies have shown that compared with the healthy control group, the serum miR-195 level in the early BC group decreased by more than two times, suggesting that miR-195 may be used as a biological marker for early diagnosis of BC.
[0088] In addition, the study also found that both complementary mature miRNAs of miR-195 have good diagnostic value. Among the five single miRNAs studied, mir-195-5p showed the best diagnostic ability, showing excellent sensitivity and specificity (65% and 100%, respectively). In the constructed diagnostic panel, mir-195-3p is the only miRNA overexpressed in breast cancer. Previous studies have reported the relationship between mir-195-3p and breast cancer. However, the pathogenesis of mir-195-3p in breast cancer has not been studied so far. mir-195-5p is considered to be a new prognostic marker for rectal cancer. In cervical cancer, the expression of mir-195-5p is lower than that of the control group, which may inhibit the malignant progression of cervical cancer by targeting YAP1. These studies provide evidence that miR-195 may be used as a biological indicator for BC diagnosis.
[0089] Previous studies have reported that the miR-10b family is involved in the occurrence and metastasis of various tumors. It has been reported that the expression level of serum miR-10b-5p is significantly increased in patients with early hepatocellular carcinoma (HCC), and miR-10b-5p has a high diagnostic value (ROC = 0.934). Studies have found that miR-10b-5p expression is significantly correlated with the molecular subtypes of early invasive ductal carcinoma. At the same time, further studies have found that high expression of miR-10b-5p is a protective factor for patients with invasive ductal carcinoma of the breast, which can reduce recurrence and mortality, and may become a potential therapeutic target for patients with invasive ductal carcinoma of the breast. Studies have shown that miR-10b-5p can be used as a new biomarker for the diagnosis and prognosis of breast cancer patients.
[0090] Miracle-133a-3p was also found to be an important regulator of HCC and could be used as a non-invasive biomarker for the diagnosis of HCC patients (AUC = 0.67). Miracle-133a-3p has a strong ability to distinguish breast cancer from benign breast diseases (ACU = 0.84).
[0091] As a miRNA that regulates the core role of cancer, miR-155 has been found to be highly correlated with gynecological tumors, digestive system tumors and blood system tumors. More and more evidence shows that its 3p chain plays a certain role in these areas. Studies have found that the expression level of miR-155-3p can be used as a biomarker for early BC diagnosis with high sensitivity, specificity and accuracy.
[0092] There are several advantages to the use of miRNA-based biomarkers, including their stability in serum samples, non-invasive detection, and potential for early diagnosis. This study screened out five miRNAs with greater correlation with BC through clinical samples to draw a diagnostic model with higher diagnostic efficacy, overcoming the shortcomings of single miRNA diagnosis, better distinguishing BC populations from benign breast disease populations, and providing the possibility of early diagnosis of BC with a combined model. At present, some scholars have also found that some miRNAs can be used as potential diagnostic markers for BC patients. Our study included five miRNAs with individual diagnostic efficacy, and the diagnostic model composed of mir-10b-5p, mir-133a-3p, mir-195-5p, mir-195-3p, and mir-155-3p was developed as a diagnostic marker for BC, which will help timely intervention and treatment decisions and improve patient management. However, further validation studies in larger cohorts are still needed to confirm the diagnostic accuracy and clinical utility of these miRNAs.
[0093] in conclusion
[0094] In this study, we preliminarily identified serum miRNAs markers associated with BC and found 5 serum miRNAs that can be used for breast cancer screening and early diagnosis. In addition, we successfully constructed a diagnostic panel with excellent diagnostic performance, sensitivity and specificity using these 5 miRNAs, providing a new possibility for early diagnosis of BC.
[0095] The specification of the present invention describes the specific implementation scheme in detail. Those skilled in the art should recognize that the above implementation scheme is exemplary and cannot be understood as limiting the present invention. For those skilled in the art, without departing from the principle of the present invention, by making several improvements and modifications to the present invention, the technical solutions obtained by these improvements and modifications also fall within the scope of protection of the claims of the present invention.
Claims
1. A biomarker for tumor detection, It is characterized in that The biomarkers include at least one of mir-21-3p, mir-10b-5p, mir-133a-3p, mir-195-5p, and mir-155-3p.
2. A biomarker for tumor detection according to claim 1, It is characterized in that The biomarkers include: miR-155-3p; and At least one of mir-21-3p, mir-10b-5p, mir-133a-3p, and mir-195-5p.
3. A biomarker for tumor detection according to claim 2, It is characterized in that The biomarkers include miR-10b-5p, miR-133a-3p and miR-195-5p.
4. A biomarker for tumor detection according to claim 3, It is characterized in that The biomarkers include miR-10b-5p, miR-133a-3p, miR-155-3p and miR-195-5p.
5. A biomarker for tumor detection according to claim 4, It is characterized in that The biomarkers include mir-21-3p, mir-10b-5p, mir-133a-3p, mir-195-5p and mir-155-3p.
6. A biomarker for tumor detection according to claim 5, It is characterized in that The biomarkers include mir-21-3p, mir-10b-5p, mir-133a-3p, mir-195-5p and mir-155-3p in the blood.
7. A biomarker for tumor detection according to claim 1, It is characterized in that The tumor is breast cancer, gastric cancer, lung cancer, esophageal cancer, colorectal cancer, pancreatic cancer, and liver cancer.
8. A biomarker for tumor detection according to claim 7, It is characterized in that The tumor is breast cancer.
Citation Information
Patent Citations
Breast cancer molecular marker miR-195-5p
CN102676522A
Serum miRNA marker combination for screening early breast cancer and application of serum miRNA marker combination
CN108004318A
Serum miRNA marker combination for auxiliary diagnosis of breast cancer and detection kit of serum miRNA marker combination
CN114381519A
Circulating microRNA group for early detection of breast cancer and method thereof
CN118043484A
